🏛️ Verified NIH Record • Updated 2026-08-11
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease (NCT06585449)
A Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered Single Ascending Doses of ALN-HTT02 in Adult Patients With Huntington's Disease
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Alnylam Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Edmonton
Age range: 25 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Clinical Trial Site — Edmonton,
- Clinical Trial Site — Montreal,
- Clinical Trial Site — Ottawa,
- Clinical Trial Site — Vancouver,
- Clinical Trial Site — Berlin,
- Clinical Trial Site — Bochum,
- Clinical Trial Site — Bonn,
- Clinical Trial Site — Dresden,
- Clinical Trial Site — Münster,
- Clinical Trial Site — Taufkirchen,
- Clinical Trial Site — Ulm,
- Clinical Trial Site — Birmingham,
- Clinical Trial Site — Cambridge,
- Clinical Trial Site — Cardiff,
- Clinical Trial Site — Glasgow,
- Clinical Trial Site — Greater Manchester,
- Clinical Trial Site — London,
- Clinical Trial Site — Oxford,
- Clinical Trial Site — Plymouth,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Huntington's Disease
- Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease — Birmingham, Alabama
- HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease — Englewood, Colorado
- Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort — Birmingham, Alabama
Explore by condition: All Huntington's Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.